Alexion Pharmaceuticals Inc. (ALXN) Stock Rating Reaffirmed by FBR & Co

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “hold” rating reissued by FBR & Co in a note issued to investors on Monday.

ALXN has been the subject of a number of other research reports. Vetr cut shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $107.00 price objective for the company. in a report on Tuesday, October 18th. Jefferies Group cut their price objective on shares of Alexion Pharmaceuticals from $140.00 to $120.00 and set a “hold” rating for the company in a report on Friday, September 23rd. Leerink Swann lifted their price objective on shares of Alexion Pharmaceuticals from $210.00 to $211.00 and gave the company an “outperform” rating in a report on Monday, September 26th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 27th. Finally, Citigroup Inc. lifted their price objective on shares of Alexion Pharmaceuticals from $154.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, September 20th. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $173.36.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 120.36 on Monday. The stock has a market capitalization of $26.98 billion, a PE ratio of 73.39 and a beta of 1.45. Alexion Pharmaceuticals has a 12 month low of $110.56 and a 12 month high of $193.45. The stock’s 50 day moving average is $123.44 and its 200 day moving average is $130.09.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The firm earned $799 million during the quarter, compared to analysts’ expectations of $787.07 million. During the same quarter last year, the company posted $1.16 earnings per share. The firm’s revenue was up 19.9% compared to the same quarter last year. Analysts anticipate that Alexion Pharmaceuticals will post $4.64 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, Director Leonard Bell sold 37,317 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $140.38, for a total transaction of $5,238,560.46. Following the completion of the transaction, the director now owns 440,936 shares in the company, valued at approximately $61,898,595.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Carsten Thiel sold 4,584 shares of the business’s stock in a transaction that occurred on Friday, October 14th. The stock was sold at an average price of $120.28, for a total transaction of $551,363.52. Following the transaction, the executive vice president now owns 32,741 shares of the company’s stock, valued at approximately $3,938,087.48. The disclosure for this sale can be found here. Company insiders own 4.41% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Global X Management Co. LLC boosted its position in shares of Alexion Pharmaceuticals by 1,416.4% in the third quarter. Global X Management Co. LLC now owns 925 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 864 shares during the last quarter. Cornerstone Advisors Inc. boosted its position in shares of Alexion Pharmaceuticals by 47.4% in the third quarter. Cornerstone Advisors Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 310 shares during the last quarter. NEXT Financial Group Inc boosted its position in shares of Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 440 shares during the last quarter. Acrospire Investment Management LLC boosted its position in shares of Alexion Pharmaceuticals by 50.0% in the third quarter. Acrospire Investment Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 400 shares during the last quarter. Finally, Bellwether Investment Group LLC bought a new position in shares of Alexion Pharmaceuticals during the second quarter valued at about $172,000. Institutional investors own 97.33% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2016 Mideast Time.